Genelux Corp
GNLX
NASDAQ
Biotechnology
$2.74
USD
+0.11 (+4.18%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $121.97M
Volume 458.9K
Revenue
$8,000
TTM
— YoY
Gross Margin
100%
TTM
— YoY
Net Income
$-33.58M
TTM
-13.8%
YoY
Operating Cash Flow
$-25.89M
TTM
-16.1%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | -100.0% | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 3.1 | 3.0 | 3.5 | 3.8 | 3.4 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 7.8 | 7.8 | 8.2 | 9.4 | 9.2 |
Operating Income | -7.8 | -7.8 | -8.2 | -9.4 | -9.2 |
EBITDA | -7.8 | -7.7 | -8.1 | -9.4 | -9.2 |
Other Income / Expense | 0.1 | 0.1 | 0.1 | 0.0 | 0.1 |
Total Other Income / Expense | 0.3 | 0.3 | 0.2 | 0.2 | 0.2 |
Income Before Income Taxes | -7.5 | -7.5 | -8.0 | -9.2 | -8.9 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -7.5 | -7.5 | -8.0 | -9.2 | -8.9 |
Consolidated Net Income / Loss | -7.5 | -7.5 | -8.0 | -9.2 | -8.9 |
Net Income Attributable to Common Shareholders | -7.5 | -7.5 | -8.0 | -9.2 | -8.9 |
Basic EPS | -$0.21 | -$0.20 | -$0.21 | -$0.24 | -$0.20 |
Diluted EPS | -$0.21 | -$0.20 | -$0.21 | -$0.24 | -$0.20 |
Basic Shares Outstanding | 34.9M | 37.9M | 37.9M | 37.9M | 44.2M |
Diluted Shares Outstanding | 34.9M | 37.9M | 37.9M | 37.9M | 44.2M |